Publications
Detailed Information
HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Ji-Won | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Kim, Yu Jung | - |
dc.contributor.author | Han, Hye-Suk | - |
dc.contributor.author | Kim, Jin-Soo | - |
dc.contributor.author | Lee, Kyung-Hun | - |
dc.contributor.author | Kim, Tae-Yong | - |
dc.contributor.author | Han, Sae-Won | - |
dc.contributor.author | Jeon, Yoon Kyung | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Park, In Ae | - |
dc.date.accessioned | 2022-03-22T09:06:04Z | - |
dc.date.available | 2022-03-22T09:06:04Z | - |
dc.date.created | 2021-04-13 | - |
dc.date.created | 2021-04-13 | - |
dc.date.issued | 2013-07 | - |
dc.identifier.citation | Cancer Chemotherapy and Pharmacology, Vol.72 No.1, pp.109-115 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.other | 127798 | - |
dc.identifier.uri | https://hdl.handle.net/10371/177142 | - |
dc.description.abstract | This study aimed to elucidate the clinical implication of human epidermal growth factor receptor 2/centromeric probe for chromosome 17 (HER2/CEP17) ratio and HER2 immunohistochemistry (IHC) results in patients with HER2 fluorescence in situ hybridization (FISH)-positive metastatic breast cancer (MBC) who received first-line trastuzumab plus taxane chemotherapy. Using clinical data of patients with HER2 FISH-positive MBC who received first-line trastuzumab plus taxane chemotherapy, we analyzed the clinical outcome according to the HER2/CEP17 ratio and HER2 IHC analysis. Fifty-two women were analyzed. The median age was 50 years (range 27-69 years). Patients with a HER2/CEP17 ratio a parts per thousand yen3.0 had significantly longer progression-free survival (PFS) (17.2 vs. 7.4 months; p = 0.002) with a tendency toward higher response rate (RR) (p = 0.325) and longer overall survival (OS) (p = 0.129). Patients with HER2 IHC 1+ had significantly shorter OS (14.0 vs. 42.4 months; p = 0.013) along with a tendency toward lower RR (p = 0.068) and shorter PFS (p = 0.220). In the multivariate analysis, HER2/CEP17 ratio < 3.0 (p = 0.004) and Eastern Cooperative Oncology Group (ECOG) PS 2 (p = 0.015) were significant factors for shorter PFS, and HER2 IHC 1+ (p = 0.015) and ECOG PS 2 (p = 0.036) were significant factors for poor OS. Our data support that HER2/CEP17 ratios and HER2 IHC scores may predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 FISH-positive MBC. | - |
dc.language | 영어 | - |
dc.publisher | Springer Verlag | - |
dc.title | HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1007/s00280-013-2174-1 | - |
dc.citation.journaltitle | Cancer Chemotherapy and Pharmacology | - |
dc.identifier.wosid | 000320889300011 | - |
dc.identifier.scopusid | 2-s2.0-84879797941 | - |
dc.citation.endpage | 115 | - |
dc.citation.number | 1 | - |
dc.citation.startpage | 109 | - |
dc.citation.volume | 72 | - |
dc.identifier.sci | 000320889300011 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Kim, Jee Hyun | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Jeon, Yoon Kyung | - |
dc.contributor.affiliatedAuthor | Oh, Do-Youn | - |
dc.contributor.affiliatedAuthor | Kim, Tae-You | - |
dc.contributor.affiliatedAuthor | Park, In Ae | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | PHASE-II TRIAL | - |
dc.subject.keywordPlus | GENE AMPLIFICATION | - |
dc.subject.keywordPlus | ADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | WEEKLY PACLITAXEL | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | HER2 | - |
dc.subject.keywordAuthor | Fluorescent in situ hybridization | - |
dc.subject.keywordAuthor | Breast cancer | - |
dc.subject.keywordAuthor | Trastuzumab | - |
dc.subject.keywordAuthor | Taxane | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.